The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor

详细信息    查看全文

• 作者：Jeung Kuk Park^a ; ^&dagger ; ; Sunmin Kim^a ; ^&dagger ; ; Yu Jin Han^a ; Seong Hwan Kim^b ; Nam Sook Kang^c ; Hyuk Lee^d ; ^{leeh@krict.re.kr" class="auth_mail" title="E-mail the corresponding author} ; SangYoun Park^a ; ^{psy@ssu.ac.kr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：PAK4 ; Inhibitor ; FBDD ; Cancer ; Drug discovery
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：1 June 2016
• 年：2016
• 卷：26
• 期：11
• 页码：2580-2583
• 全文大小：982 K

文摘

p21-Activated kinases (PAKs) which belong to the family of ste20 serine/threonine protein kinases regulate cytoskeletal reorganization, cell motility, cell proliferation, and oncogenic transformation which are all related to the cellular functions during cancer induction and metastasis. The fact that PAK mutations are detected in multiple tumor tissues makes PAKs a novel therapeutic drug target. In this study, an imidazo[4,5-b]pyridine-based PAK4 inhibitor, KY-04045 (6-Bromo-2-(3-isopropyl-1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridine), was discovered using a virtual site-directed fragment-based drug design and was validated using an inhibition assay. Although PAK4 affinity to KY-04045 seems much weaker than that of the reported PAK4 inhibitors, the location of KY-04045 is clearly defined in the structure of PAK4 co-crystallized with KY-04045. The crystal structure illustrates that the pyrazole and imidazopyridine rings of KY-04045 are sufficient for mediating PAK4 hinge loop interaction. Hence, we believe that KY-04045 can be exploited as a basic building block in designing novel imidazo[4,5-b]pyridine-based PAK4 inhibitors.